First National Bank of South Miami reduced its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 11.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,895 shares of the company’s stock after selling 240 shares during the quarter. First National Bank of South Miami’s holdings in Eli Lilly and Company were worth $889,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of LLY. Silicon Valley Capital Partners bought a new stake in Eli Lilly and Company during the 1st quarter worth about $25,000. Bogart Wealth LLC grew its position in shares of Eli Lilly and Company by 193.3% during the 1st quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock worth $30,000 after buying an additional 58 shares during the period. Laffer Tengler Investments bought a new stake in shares of Eli Lilly and Company during the first quarter worth approximately $33,000. Tanglewood Legacy Advisors LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $37,000. Finally, Freedom Wealth Alliance LLC bought a new position in Eli Lilly and Company in the fourth quarter valued at approximately $37,000. 81.38% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 107,022 shares of the company’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $459.28, for a total value of $49,153,064.16. Following the transaction, the insider now directly owns 101,248,810 shares in the company, valued at $46,501,553,456.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, EVP Alonzo Weems sold 1,148 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total value of $678,445.04. Following the transaction, the executive vice president now owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 107,022 shares of the firm’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $459.28, for a total transaction of $49,153,064.16. Following the transaction, the insider now directly owns 101,248,810 shares in the company, valued at $46,501,553,456.80. The disclosure for this sale can be found here. Insiders have sold a total of 976,153 shares of company stock valued at $21,080,192,113 over the last 90 days. 0.13% of the stock is currently owned by insiders.
Analyst Ratings Changes
Eli Lilly and Company Price Performance
Shares of LLY opened at $571.17 on Tuesday. The company has a market cap of $542.21 billion, a price-to-earnings ratio of 79.44, a PEG ratio of 2.37 and a beta of 0.32. Eli Lilly and Company has a 1-year low of $296.32 and a 1-year high of $601.84. The company’s fifty day simple moving average is $512.56 and its 200 day simple moving average is $439.28. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 1.63.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.13. The business had revenue of $8.31 billion for the quarter, compared to the consensus estimate of $7.58 billion. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.25 earnings per share. On average, research analysts forecast that Eli Lilly and Company will post 9.84 earnings per share for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date was Monday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 62.87%.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Five stocks we like better than Eli Lilly and Company
- EV Stocks and How to Profit from Them
- 2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally
- Dividend Tax Calculator
- Got Nuclear? Three Stocks To Play Energy’s Next Frontier
- How is Compound Interest Calculated?
- The Top 4 Utilities for Value, Yield, and Upside Potential
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.